^
    21h
    CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov)
    P2, N=80, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 positive
    |
    zeprumetostat (SHR-2554) • Lunsumio (mosunetuzumab-axgb)
    2d
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (clinicaltrials.gov)
    P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD)
    2d
    Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial. (PubMed, Hemasphere)
    We leveraged the Phase III Fondazione Italiana Linfomi FOLL12 trial, which treated patients with advanced-stage FL with R-CHOP or R-Bendamustine, to evaluate the role of myeloid CH at baseline and after chemoimmunotherapy (CIT). Patients acquiring fit DDR clones (N = 37) had inferior long-term outcomes, including independent increased risk of second malignancies (hazard ratio [HR] 2.63, P = 0.035) that developed in 28 patients, and shorter OS (HR 3.28, P = 0.008). CH emerges as a novel and potentially valuable biomarker in FL, capable of predicting long-term toxicities that are key endpoints in indolent lymphoid malignancies characterized by long-lasting survival.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TP53 mutation • TET2 mutation
    |
    Rituxan (rituximab) • bendamustine
    2d
    Genomic heterogeneity in primary cutaneous follicular center lymphomas reveals different clinicopathological subgroups. (PubMed, Hemasphere)
    This analysis supports a model of PCFCL oncogenesis driven by circulating progenitors following complex evolutionary patterns, including convergent evolution and greater clonal diversity at relapse. Overall, our study refines the mechanisms driving PCFCL pathogenesis, while providing a framework for PCFCL differential diagnosis and clinical management.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • KMT2D (Lysine Methyltransferase 2D) • B2M (Beta-2-microglobulin) • CREBBP (CREB binding protein) • EP300 (E1A binding protein p300) • IRF8 (Interferon Regulatory Factor 8) • TNFRSF14 (TNF Receptor Superfamily Member 14) • MME (Membrane Metalloendopeptidase) • STAT6 (Signal transducer and activator of transcription 6) • FCER2 (Fc Fragment Of IgE Receptor II)
    3d
    Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series. (PubMed, Leuk Lymphoma)
    In this contemporary POL series, clinicopathologic heterogeneity was prominent, and laboratory profiles frequently overlapped with ovarian malignancy work-up. Outcomes may be favorable among patients receiving timely, subtype-appropriate systemic treatment.
    Retrospective data • Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9)
    5d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5d
    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=439, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2029 --> Jul 2041
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    5d
    A Long-term Extension Study of PCI-32765 (Ibrutinib) (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2027 --> Dec 2029
    Trial completion date
    |
    Imbruvica (ibrutinib)
    6d
    Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=38, Recruiting, Yazeed Sawalha | Trial completion date: Dec 2028 --> Oct 2027 | Trial primary completion date: Dec 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    Imbruvica (ibrutinib) • Epkinly (epcoritamab-bysp)
    6d
    KILT: Study of Lacutamab in Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, The Lymphoma Academic Research Organisation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    |
    gemcitabine • lacutamab (IPH4102)
    6d
    Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse (clinicaltrials.gov)
    P2, N=65, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Oct 2027 --> Dec 2028 | Trial primary completion date: Jan 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    golcadomide (CC-99282)
    7d
    Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Jaypirca (pirtobrutinib)